{"organizations": [], "uuid": "15a550b5a8053063b625e99a26f085131ee0abaa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fate-therapeutics-announces-additi/brief-fate-therapeutics-announces-additional-clinical-data-from-phase-1-stage-of-protect-clinical-trial-of-protmune-idUSASC09SRJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T14:27:00.000+02:00", "replies_count": 0, "uuid": "15a550b5a8053063b625e99a26f085131ee0abaa"}, "author": "", "url": "https://www.reuters.com/article/brief-fate-therapeutics-announces-additi/brief-fate-therapeutics-announces-additional-clinical-data-from-phase-1-stage-of-protect-clinical-trial-of-protmune-idUSASC09SRJ", "ord_in_thread": 0, "title": "BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fate therapeutics inc", "sentiment": "none"}, {"name": "protect clinical trial of protmune reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 12:28 PM / Updated 8 minutes ago BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune Reuters Staff 1 Min Read March 19 (Reuters) - Fate Therapeutics Inc: * FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™ * FATE THERAPEUTICS INC - ‍NO EVENTS OF CANCER RELAPSE HAVE OCCURRED WITH PROTMUNE IN PHASE 1 STAGE OF PROTECT​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T14:27:00.000+02:00", "crawled": "2018-03-19T14:38:45.007+02:00", "highlightTitle": ""}